The present specification discloses a pharmaceutical composition comprising anactive agent that causesreduction of the level of systemic immunosuppression in an individual for usein treating a disease,disorder, condition or injury of the CNS. The pharmaceutical composition isadministered by a dosageregimen comprising at least one course of therapy, each course of therapycomprising in sequence atreatment session followed by an interval session of non-treatment.